Key result
Long-term blockade of AT1 receptors with L-158,809 in rats with chronic nephritis decreased blood pressure and normalized urinary albumin excretion, being as effective as ACE inhibition.
Why the study?
Does AT1 receptor antagonism or ACE inhibition improve blood pressure and albuminuria in rats with autoimmune nephritis?
Does AT1 receptor antagonism or ACE inhibition improve blood pressure and albuminuria in rats with autoimmune nephritis?
Answers are grounded in this paper and cite their sources.
Long-term blockade of AT1 receptors in chronic nephritis is as effective as ACE inhibition in reducing blood pressure and albuminuria, potentially mediated by cGMP production.
AIMS: We investigated angiotensin II and nitric oxide-cGMP pathway in the development of hypertension and renal damage in chronic experimental nephritis. METHODS: Rats with autoimmune nephritis were treated for 12 weeks with AT1 receptor antagonist L-158,809 and/or ACE inhibitor captopril given in drinking water. Blood pressure, urinary albumin, and urinary excretion of cGMP were measured. Renal density of ACE, AT1 and AT2 receptors was determined by quantitative in vitro autoradiography. RESULTS: L-158,809, captopril, and their combination decreased blood pressure and normalised urinary albumin excretion rate in rats with nephritis. In L-158,809-treated rats, cGMP excretion was increased compared to the vehicle-treated nephritic group suggesting that the dysfunctional nitric oxide system may be activated by angiotensin antagonism. In nephritic rats, AT1 and AT2 receptor binding densities in renal medulla were decreased, cortical AT receptor expression remained unchanged. Following L-158,809 treatment, both AT1 and AT2 receptor binding was suppressed. CONCLUSION: Long-term blockade of AT1 receptors in chronic nephritis has beneficial effects both on albuminuria and blood pressure being as effective as ACE inhibition or their combination. The stimulatory effect of AT1 receptor antagonism on cGMP production was not mediated by AT2 receptor-dependent mechanisms suggesting that AT1 receptor blockade per se favours activation of humoral pathways that stimulate cGMP production and potentially contribute to renal protection in chronic nephritis.
No takes yet. Share an insight, caveat, or question.
Uhlenius et al. (2002) studied Chronic experimental nephritis. AT1 receptor antagonist L-158,809 and/or ACE inhibitor captopril vs. Vehicle-treated nephritic group was evaluated on Blood pressure, urinary albumin, and urinary excretion of cGMP. Long-term blockade of AT1 receptors with L-158,809 in rats with chronic nephritis decreased blood pressure and normalized urinary albumin excretion, being as effective as ACE inhibition.
Synapse has enriched 10 related papers. Consider them for comparative context: